Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 20/20 | 0.59 |
| ▸ | PPARG | P37231 | 17/20 | 0.59 |
| ▸ | PPARD | Q03181 | 16/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12083342 | 0.89 | PPARA (0.57) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL2031380 | 0.88 | PPARA (0.56) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL1934856 | 0.88 | PPARA (0.49) | PPARAPPARGPPARD | |
| SCHEMBL2031382 | 0.88 | PPARA (0.56) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL2029938 | 0.86 | PPARA (0.54) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL2032852 | 0.86 | PPARA (0.54) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL1934970 | 0.86 | PPARA (0.44) | PPARAPPARGPPARD | |
| SCHEMBL1934452 | 0.86 | PPARA (0.44) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL1934897 | 0.86 | NPC1 (0.56) | PPARAPPARGPPARD | |
| SCHEMBL1934554 | 0.86 | PPARA (0.58) | PPARAPPARGPPARDCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070128-A | Primary biliary nature treatment of cholangitis | 基恩菲特公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122055145-A | For treating primary biliary diseases Angstrom of cholangitis Lafeibulon | 基恩菲特公司 | 2026-05-15 | — | — | CN | claimed |
| US-20240216312-A1 | PPAR-AGONISTS FOR USE IN THE TREATMENT OF LIVER FAILURE | GENFIT (FR) | 2024-07-04 | — | — | US | claimed |
| US-20240216313-A1 | ELAFIBRANOR DERIVATIVES AGONISTS OF PPAR FOR USE IN THE TREATMENT OF SEPSIS | GENFIT (FR) | 2024-07-04 | — | — | US | claimed |
| EP-4337184-A1 | PPAR-AGONISTS FOR USE IN THE TREATMENT OF LIVER FAILURE | Genfit (FR) | 2024-03-20 | — | — | EP | claimed |
| EP-4337185-A1 | ELAFIBRANOR DERIVATIVES AGONISTS OF PPAR FOR USE IN THE TREATMENT OF SEPSIS | Genfit (FR) | 2024-03-20 | — | — | EP | claimed |
| US-20230165821-A1 | ELAFIBRANOR FOR THE TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS | GENFIT (FR) | 2023-06-01 | — | — | US | claimed |
| EP-4153156-A1 | ELAFIBRANOR FOR THE TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS | Genfit (FR) | 2023-03-29 | — | — | EP | claimed |
| US-20230052189-A1 | TREATMENT OF PRIMARY BILIARY CHOLANGITIS WITH ELAFIBRANOR | GENFIT (FR) | 2023-02-16 | — | — | US | claimed |
| CN-115605192-A | Irafenib for the treatment of primary sclerosing cholangitis | 基恩菲特公司（FR） | 2023-01-13 | — | — | CN | claimed |
| EP-2046715-B1 | SUBSTITUTED 1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES THEREOF | GENFIT (FR) | 2014-04-16 | — | — | EP | claimed |
| EP-2504005-B1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2013-11-06 | — | — | EP | claimed |
| EP-2641596-A1 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | Genfit (FR) | 2013-09-25 | — | — | EP | claimed |
| US-20120252725-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2012-10-04 | — | — | US | claimed |
| EP-2504005-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | Genfit (FR) | 2012-10-03 | — | — | EP | claimed |
| US-20110136888-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | GENFIT (FR) | 2011-06-09 | — | — | US | claimed |
| WO-2011064350-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2011-06-03 | — | — | WO | claimed |
| US-20100286276-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | GENFIT (FR) | 2010-11-11 | — | — | US | claimed |
| EP-2046715-A1 | SUBSTITUTED 1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES THEREOF | Genfit (FR) | 2009-04-15 | — | — | EP | claimed |
| WO-2007147879-A1 | SUBSTITUTED 1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES THEREOF | GENFIT (FR) | 2007-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216313-A1 | ELAFIBRANOR DERIVATIVES AGONISTS OF PPAR FOR USE IN THE TREATMENT OF SEPSIS | PPARD, PPARA, PPARG | PPARA 2/4885PPARG 3/4885PPARD 1/4885 |
| US-20110136888-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | DPP3, DPP4, CYP3A43 | PPARA 16/4885PPARG 84/4885PPARD 15/4885 |
| US-20240216312-A1 | PPAR-AGONISTS FOR USE IN THE TREATMENT OF LIVER FAILURE | PPARA, PPARD, FABP1 | PPARA 1/4885PPARG 4/4885PPARD 2/4885 |
| US-20120252725-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT1, GOT2 | PPARA 251/4885PPARG 315/4885PPARD 349/4885 |
| US-20100286276-A1 | Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof | DPP3, DPP8, DPP4 | PPARA 11/4885PPARG 56/4885PPARD 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.